Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495790 · ClinicalTrials.gov registry record
AIMS Cancer Outcomes Study
A clinical trial of Advanced Solid Tumor and Neoplasms, sponsored by Advanced Integrative Medical Science Institute.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04495790 is a study of Advanced Solid Tumor and Neoplasms that is actively recruiting participants, run by Advanced Integrative Medical Science Institute. The registered enrollment target is 500 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04495790, a study of Advanced Solid Tumor and Neoplasms, is actively recruiting participants, sponsored by Advanced Integrative Medical Science Institute.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Conditions Studied
Study Locations (1)
Washington
- AIMS Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495790
The ClinicalTrials.gov registry entry for NCT04495790 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (163% higher). The listed sponsor is Advanced Integrative Medical Science Institute, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT04495790 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04495790 about?
NCT04495790 is a clinical study titled "AIMS Cancer Outcomes Study". The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect d...
What is the current status of trial NCT04495790?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-05-18. Estimated completion is 2030-12-31.
What conditions does trial NCT04495790 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Neoplasms, Advanced Cancer, Oncology, Neoplasm Malignant.
Who is sponsoring clinical trial NCT04495790?
This trial is sponsored by Advanced Integrative Medical Science Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04495790 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.